Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Varian, a Siemens Healthineers Company
EMD Serono
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
The New York Proton Center
Travera Inc
Association Francaise pour la Recherche Thermale
University Health Network, Toronto
Jazz Pharmaceuticals
Alliance for Clinical Trials in Oncology
Fate Therapeutics
DualityBio Inc.
Conjupro Biotherapeutics, Inc.
Eastern Cooperative Oncology Group
International Agency for Research on Cancer
The Second Affiliated Hospital of Hainan Medical University
GlaxoSmithKline
Terremoto Biosciences Inc.
Stanford University
Ensem Therapeutics
Varian, a Siemens Healthineers Company
PMV Pharmaceuticals, Inc
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
UMC Utrecht
University of Chicago
University of California, Irvine
Eli Lilly and Company
ViroMissile, Inc.
Hospices Civils de Lyon
University Health Network, Toronto
Kaiser Permanente
Duke University
Washington University School of Medicine
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Poseida Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
University of Colorado, Denver
MacroGenics
Avacta Life Sciences Ltd
SystImmune Inc.